1. Home
  2. APPN vs NVAX Comparison

APPN vs NVAX Comparison

Compare APPN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Appian Corporation

APPN

Appian Corporation

HOLD

Current Price

$23.19

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.46

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPN
NVAX
Founded
1999
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.6B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
APPN
NVAX
Price
$23.19
$8.46
Analyst Decision
Hold
Hold
Analyst Count
6
9
Target Price
$33.83
$11.33
AVG Volume (30 Days)
633.3K
4.4M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
309.76
EPS
0.02
2.58
Revenue
$226,743,000.00
$1,123,479,000.00
Revenue This Year
$13.79
N/A
Revenue Next Year
$10.56
N/A
P/E Ratio
$1,199.50
$3.47
Revenue Growth
28.29
64.69
52 Week Low
$21.77
$5.01
52 Week High
$46.06
$11.85

Technical Indicators

Market Signals
Indicator
APPN
NVAX
Relative Strength Index (RSI) 34.36 38.12
Support Level $21.77 $8.01
Resistance Level $31.10 $9.05
Average True Range (ATR) 0.95 0.54
MACD -0.16 -0.23
Stochastic Oscillator 4.89 1.81

Price Performance

Historical Comparison
APPN
NVAX

About APPN Appian Corporation

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: